Who are dalpiciclib + capecitabine + endocrine therapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dalpiciclib-capecitabine-endocrine-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

dalpiciclib + capecitabine + endocrine therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

dalpiciclib + capecitabine + endocrine therapy (dalpiciclib + capecitabine + endocrine therapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CDK4/6 inhibitor + chemotherapy + endocrine therapy. Area: Oncology.

phase 3 CDK4/6 inhibitor + chemotherapy + endocrine therapy CDK4/6, estrogen receptors Oncology Small molecule Live · refreshed every 30 min

Target snapshot

dalpiciclib + capecitabine + endocrine therapy (dalpiciclib + capecitabine + endocrine therapy) — Fujian Cancer Hospital. Dalpiciclib is a CDK4/6 inhibitor that blocks the cell cycle, while capecitabine is a chemotherapy medication that interferes with DNA synthesis, and endocrine therapy targets hormone receptors to slow cancer growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
dalpiciclib + capecitabine + endocrine therapy TARGET	dalpiciclib + capecitabine + endocrine therapy	Fujian Cancer Hospital	phase 3	CDK4/6 inhibitor + chemotherapy + endocrine therapy	CDK4/6, estrogen receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CDK4/6 inhibitor + chemotherapy + endocrine therapy class)

Fujian Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). dalpiciclib + capecitabine + endocrine therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/dalpiciclib-capecitabine-endocrine-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab